Suvorexant

• Insomnia
• Sleep Onset Insomnia
• Sleep Maintenance Insomnia
• Chronic Insomnia

Suvorexant, sold as Belsomra, was the first dual orexin receptor antagonist (DORA) approved for chronic insomnia and represents a mechanism distinct from benzodiazepines, Z-drugs, sedating antidepressants, and antihistamines. Rather than potentiating GABA inhibition or sedating broadly, it reduces wake drive — an approach that may better preserve sleep architecture and reduce the morning hangover, dependency, and tolerance concerns of older hypnotics. It is FDA-approved as a Schedule IV medication for insomnia characterized by difficulties with sleep onset and/or sleep maintenance and is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets to allow individualized dosing.

Mechanism of Action

Orexin (also called hypocretin) neurons in the lateral hypothalamus release the neuropeptides orexin A and B, which act on OX1R and OX2R receptors throughout the brain to promote and stabilize wakefulness, regulate appetite, and modulate reward circuits. Orexin signaling is high during waking hours, drops sharply at sleep onset, and is near silent during sleep; selective loss of orexin neurons is the established cause of narcolepsy with cataplexy, which is why narcolepsy is a contraindication to suvorexant. By competitively blocking both OX1R and OX2R, suvorexant reduces the wake-promoting drive at bedtime and allows sleep to occur without directly enhancing inhibitory GABA tone. Because it does not directly enhance GABA, it does not cause the muscle relaxation, anterograde amnesia, and fall risk traditionally associated with benzodiazepines, although next-day impairment can still occur and is dose-dependent. Sleep architecture is largely preserved, including REM sleep, which may be particularly important for cognitive consolidation. The NHLBI insomnia overview and American Academy of Sleep Medicine clinical practice guidelines detail current pharmacologic approaches.

Clinical Use

For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment per AASM guidelines and outperforms medication for long-term outcomes, with benefits sustained well after treatment ends. Pharmacotherapy is appropriate when CBT-I is unavailable, has failed, or while it is being arranged. Among medications, the AASM guideline conditionally recommends suvorexant for sleep maintenance insomnia. Newer DORAs (lemborexant) work similarly and may be substituted based on tolerability, dosing convenience, or insurance coverage. Trazodone (often used off-label at low dose), low-dose doxepin, and the melatonin agonist ramelteon are alternatives; benzodiazepines and Z-drugs (zolpidem) are appropriate for short-term use but carry greater risk of dependence, cognitive impairment, and falls, especially in older adults — they appear on the Beers Criteria as potentially inappropriate for adults over 65. Patients with chronic generalized-anxiety-disorder-gad or untreated depression often have insomnia driven by mood — see our overview at internal-medicine/psychiatric. Coexisting sleep apnea (see sleep-apnea-diagnosis-guide) should be ruled out, as DORAs are not appropriate when untreated obstructive sleep apnea is the cause of fragmented sleep.

How to Take It

Take one tablet within 30 minutes of bedtime, allowing at least seven hours before planned awakening. Starting dose is 10 mg; if that is well tolerated but ineffective, the dose may be increased to 20 mg. The lowest effective dose should be used. Avoid taking it after a heavy meal, which delays onset by slowing absorption — administering it at least two hours after dinner produces more reliable onset. Do not take it unless you are ready to sleep — sleepiness, lapses in attention, and impaired motor coordination can occur within minutes. Avoid alcohol and other CNS depressants on the same day; combining with opioids or benzodiazepines amplifies CNS depression and respiratory risk. Drowsy driving the morning after a 20 mg dose is a documented risk; some patients should not drive at all the day after taking the higher dose. Do not increase the dose without medical guidance, and never combine doses to make up for one missed. Keep the medication secured given its Schedule IV status and the potential for misuse.

Monitoring and Follow-Up

At the four-week follow-up, assess sleep onset latency, number of awakenings, total sleep time, daytime function, and any complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating, or actions while not fully awake). Mood should be reassessed for emergent or worsening depression, including suicidal ideation, particularly in patients with underlying mood disorders — the warning extends to all hypnotics. Tolerance is uncommon in trials but should be screened periodically in long-term users. There is no required laboratory monitoring; obtain baseline labs as part of general primary care, particularly thyroid and metabolic studies, since both hypothyroidism and uncontrolled diabetes can disrupt sleep, and ferritin given the role of iron deficiency in restless legs syndrome. Our understanding-blood-work-lab-panels overview helps frame these results. Review concomitant CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir, diltiazem, verapamil) at every visit because they substantially raise drug levels and require dose reduction; strong inducers (rifampin, phenytoin, carbamazepine, St. John's wort) reduce efficacy.

Special Populations

Narcolepsy is a contraindication. Severe hepatic impairment is not recommended; mild-to-moderate impairment requires no adjustment. Patients with respiratory compromise — including chronic-obstructive-pulmonary-disease-copd or untreated obstructive sleep apnea — should be evaluated carefully because suvorexant may suppress respiratory drive at higher doses, although controlled studies have shown only modest effects in stable disease. Older adults are more susceptible to next-day impairment and falls; the lower 5 mg or 10 mg dose is preferred and most clinicians start at 5 mg in patients over 75. Pregnancy data are limited; use is not recommended in pregnancy or lactation. Pediatric safety has not been established. Patients with a history of substance use disorder should be monitored carefully, although DORAs have a lower abuse potential than benzodiazepines or Z-drugs based on current evidence. Patients with depression or anxiety should have those conditions optimized in parallel.

Drug Interactions and Practical Counseling

Suvorexant is metabolized primarily by CYP3A4. Strong inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir) substantially increase exposure and should be avoided. Moderate inhibitors (diltiazem, erythromycin, fluconazole, verapamil) require dose limitation to 5 mg. Strong inducers (rifampin, carbamazepine, phenytoin, St. John's wort) may reduce efficacy substantially. Combining with other CNS depressants — alcohol, opioids, benzodiazepines, gabapentinoids, sedating antihistamines — produces additive depression of alertness and respiration. Patients with chronic-headaches using opioid-containing analgesics should be especially cautious. Suvorexant can modestly raise digoxin levels; periodic monitoring is reasonable in patients on both. There are no significant interactions with most antidepressants used for comorbid mood disorders, although co-prescription with sedating agents may produce excessive next-day grogginess. Patients on sodium oxybate or any other sleep-active prescription should not combine with suvorexant without specialist guidance. Cannabis and CBD products carry additive sedation potential that is often underappreciated by patients.

Building a Sustainable Sleep Plan

Medication is one element of a comprehensive sleep plan. Cognitive behavioral therapy for insomnia (CBT-I) addresses the perpetuating factors — conditioned arousal, dysfunctional beliefs about sleep, irregular schedules — that medications alone cannot fix. Apps, workbooks, and certified CBT-I therapists are increasingly available. Sleep hygiene basics include a consistent wake time even on weekends, morning light exposure, daily physical activity (not too close to bedtime), avoidance of caffeine after early afternoon, limited alcohol, dim and screen-free wind-down period, and a cool, dark, quiet sleep environment. Address contributing conditions: untreated obstructive sleep apnea, restless legs syndrome, nocturia, chronic pain, anxiety, and depression all undermine sleep and amplify medication need. Our sleep-hygiene-better-rest and st-pete-circadian-rhythm-sleep-guide articles offer detailed practical guidance.

When to Contact Your Doctor

Report any episodes of doing activities while not fully awake (driving, eating, calling, leaving the house), persistent next-morning grogginess that affects driving or work, new or worsening depression, hallucinations on falling asleep or waking, sleep paralysis, or sudden muscle weakness that resembles cataplexy. Discontinuation should be discussed before stopping abruptly if the medication has been used regularly, although physiologic withdrawal is not characteristic of DORAs in the way it is for benzodiazepines.

Durable improvement in sleep usually requires more than a pill — it requires attention to sleep hygiene, daytime stress, caffeine and alcohol patterns, screen and light exposure timing, and any underlying medical and psychiatric conditions. To build a complete plan, contact us or schedule a visit.